Brought to you by 
Astellas licenses GI candidate to new Drais virtual company Seldar
07 May 2013
Executive Summary
In a deal structured similarly to one formed between the firms two months ago, Astellas Pharma Inc. and Drais Pharmaceuticals Inc. will ally in the development and commercialization of Astellas’ Phase I bombesin BB2 receptor antagonist ASP7147 for irritable bowel syndrome with diarrhea.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com